You are here: Industry Insights > Takeda

News List

Preliminary NICE ‘no’ for Takeda’s Alunbrig pharmatimes
October 11, 2018
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Takeda gets positive CHMP opinion for ALUNBRIG biospectrumasia
September 29, 2018
As part of this submission, the CHMP also reviewed data from the first interim analysis of the Phase 3 ALTA-1L trial, which met its primary endpoint...
Takeda's lung cancer treatment Alunbrig proves successful in Phase III trial pharmafile
September 27, 2018
Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease progression or death by more than 50%...
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy pharmatimes
September 27, 2018
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Takeda may sell Shire assets to reduce debt following $62-billion purchase firstwordpharma
September 14, 2018
According to people close to the situation, Takeda is considering selling Shire's eye-care business, including the dry eye disease treatment Xiidra (lifitegrast)...
Takeda set to move from Deerfield Illinois, 1000 jobs affected pharmafile
September 13, 2018
Japanese multinational Takeda is set to shut down its US headquarters in Deerfield, Illinois following the final stages of its Shire Plc acquisition.
Ambys Medicines and Takeda to develop new therapies for liver diseases pharmaceutical-technology
August 13, 2018
Ambys Medicines and Takeda Pharmaceutical Company have agreed to partner on creating new therapies for the treatment of serious liver diseases.
Takeda unite Ambys to treat serious liver disease biospectrumasia
August 13, 2018
Under the terms of the partnership agreement, Takeda has committed $100 million, including the participation in the Series A financing
Liver-focused Ambys launches with $140M, Takeda partnership fiercebiotech
August 09, 2018
Third Rock Ventures is debuting Ambys Medicines, which will develop cell and gene therapies as well as drugs for chronic liver diseases. Ambys starts life with $140 million in committed capital, including $100 million from Takeda, part of which came in th
Takeda partners with new biotech Ambys in liver disease pharmatimes
August 09, 2018
Takeda has entered into a $100 million partnership with newly-launched biotech Ambys Medicines to support its discovery and development of therapies for people with serious liver disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page